ten Bosch John Roderick sold $533K of BLLN

ten Bosch John Roderick (SVP of Laboratory Operations) sold 4,251 shares of BillionToOne, Inc. (BLLN) at $125.46 ($0.53M total) across 3 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ten Bosch John Roderick
Published Jul 15, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed open-market sale by an officer under a 10b5-1 plan is typically not a strong standalone fundamental catalyst, but it can be used by traders to gauge near-term insider selling cadence.

02

Market read

Traders may monitor whether additional insider sales occur around the same period, but this single filing alone is unlikely to drive a durable repricing.

03

What to watch

The article does not disclose any change in company performance, guidance, or new contracts, so the trading signal is primarily sentiment/positioning rather than fundamentals.

Relevance 4/10Novelty 3/10Timing: Filed 2026-07-15, discloses sale executed 2026-07-13.

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

SEC Form 4 shows SVP ten Bosch John Roderick sold 4,251 BLLN shares for about $533.3K under a 10b5-1 plan on 2026-07-13.

Expected impact

Likely minimal price impact; any effect is short-lived unless follow-on selling appears in subsequent filings.

Evidence & confidence

The filing is an open-market sale by an officer, explicitly under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes disclosed.

Market effects

No sector-level implications; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

10b5-1 plans often reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact to the headline sale.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • ten Bosch John Roderick

    SVP of Laboratory Operations who executed the sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.